key: cord-0920635-6ml12gy8
authors: Campbell, Thomas W.; Wilson, Melissa P.; Roder, Heinrich; MaWhinney, Samantha; Georgantas, Robert W.; Maguire, Laura K.; Roder, Joanna; Erlandson, Kristine M.
title: Predicting Prognosis in COVID-19 Patients using Machine Learning and Readily Available Clinical Data
date: 2021-09-23
journal: Int J Med Inform
DOI: 10.1016/j.ijmedinf.2021.104594
sha: ae35bdedae02c1777709e441031b7cab11364114
doc_id: 920635
cord_uid: 6ml12gy8

Rationale: Prognostic tools for aiding in the treatment of hospitalized COVID-19 patients could help improve outcome by identifying patients at higher or lower risk of severe disease. The study objective was to develop models to stratify patients by risk of severe outcomes during COVID-19 hospitalization using readily available information at hospital admission. Methods Hierarchical ensemble classification models were trained on a set of 229 patients hospitalized with COVID-19 to predict severe outcomes, including ICU admission, development of acute respiratory distress syndrome, or intubation, using easily attainable attributes including basic patient characteristics, vital signs at admission, and basic lab results collected at time of presentation. Each test stratifies patients into groups of increasing risk. An additional cohort of 330 patients was used for blinded, independent validation. Shapley value analysis evaluated which attributes contributed most to the models’ predictions of risk. Main Results: Test performance was assessed using precision (positive predictive value) and recall (sensitivity) of the final risk groups. All test cut-offs were fixed prior to blinded validation. In development and validation, the tests achieved precision in the lowest risk groups near or above 0.9. The proportion of patients with severe outcomes significantly increased across increasing risk groups. While the importance of attributes varied by test and patient, C-reactive protein, lactate dehydrogenase, and D-dimer were often found to be important in the assignment of risk. Conclusions Risk of severe outcomes for patients hospitalized with COVID-19 infection can be assessed using machine learning-based models based on attributes routinely collected at hospital admission.

The coronavirus disease pandemic continues to place world-wide health systems under pressure. The ability to identify patients at greatest risk of developing severe disease would help inform discussions of the risks and benefits of treatments (1-3), target higher risk populations for clinical trials of therapeutic agents, compare outcomes between patients with similar risk, and prioritize limited resources.

Multiple prognostic factors have been identified, including age, certain comorbidities (4) (5) (6) , neutrophilto-lymphocyte ratio (NLR), D-dimer and C-reactive protein (CRP) (4, (7) (8) . However, the relative influence of these factors on prognosis has been difficult to elucidate.

While traditional statistical modelling has been used to combine multiple attributes to predict outcomes for patients with COVID-19 (9-10), modern machine learning (ML) has added advantage in its capability to discover more complex interactions between correlated attributes. Such methods have shown promise for predicting acute respiratory distress syndrome (ARDS) in diseases other than COVID-19 (11) (12) and demonstrated potential utility for predicting poor outcomes in COVID-19 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) .

Many patients hospitalized with COVID-19 provide limited medical history due to not engaging in routine care, not having easily accessible comorbidities data, or being intubated shortly after arrival.

Hence, the goal of this study was to create and validate tests to risk stratify COVID-19 patients for progression to severe disease using only readily available clinical, demographic, and laboratory attributes collected at the point of hospital admission. Given the nature of these attributes, the tests stratifying risk of admission to the intensive care unit (ICU), intubation, or progression to ARDS could be validated, blinded to outcome, on an independent patient cohort using data drawn from electronic health records (EHRs).

For test development, data was collected for all patients 18 years or older admitted to the University of Colorado Health (UCH) hospital in Aurora, CO with a positive COVID-19 nasopharyngeal polymerase chain reaction test between mid-March and mid-May 2020. Attributes deemed potentially useful at the time were extracted from the EHR by medical students and stored in a REDCap database (30). Patient data was restricted to first recorded admission and observations for laboratory values and vital measures. ARDS occurrence was defined by any mention of ARDS in the critical care progress notes.

The deidentified dataset was transferred to Biodesix for test development. A set of 26 attributes (indicated with * in Table 1 ) to be used in classifier training was selected, limited to attributes routinely collected at hospital admission and available in the EHR, where inclusion of an attribute did not reduce the size of the cohort with complete data by more than 10%. The development cohort included patients with complete information for the selected attributes.

An independent validation cohort was derived from data provided by UCH's EHR data warehouse service for blinded validation of the tests. The validation cohort included all patients aged between 18 and 90 years, hospitalized in any UCH system facility with a positive COVID-19 test or diagnosis, with first admission between mid-May 2020 and mid-September 2020 with complete data on the 26 required attributes ( Figure 1 ). Deidentified data for the validation cohort were transferred to Biodesix for blinded test classification generation. Outcome data for test performance evaluation for the validation cohort was only shared after test classifications were returned to UCH investigators. ARDS occurrence was identified by SNOMED code. More details on data curation and validation are provided in the supplement. The study was reviewed and approved by the Colorado Multiple Institutional Review Board.

Machine Learning COVID-19 Risk Stratification 

A series of classifiers were trained to classify patients as higher or lower risk for each endpoint (ICU admission, intubation, ARDS) using the same set of 26 attributes that were all used in all final tests to predict risk of outcome. These classifiers were arranged in a hierarchy shown in Figure 2 to give a final classification of up to four possible risk groups. The fundamental model behind each component classifier was the Diagnostic Cortex® platform, a strongly dropout-regularized, feature abstracted, ensemble logistic regression (31). The classifier at the top of each test's hierarchy was augmented with an additional decision tree model. Hyperparameters for the models were picked on heuristic considerations as in (31) and are given in table E2, and further optimization was not performed to avoid overfitting. Bootstrap validation results in the development cohort were obtained using out-of-bag estimates (32). ML methods are described fully in the supplement, and source code demonstrating their application here is provided at (33).

A Diagnostic Cortex model with in-bag decision tree model (represented by the top box) was used to stratify the entire development cohort into a higher and lower risk group for each endpoint. Diagnostic Cortex models (middle boxes) without trees were used to split the resulting two groups further according to one of the two schemas. (Schema A was used for the tests predicting risk of any complication and intubation. Schema B was used for the tests predicting risk of ARDS and admission to the ICU.) 

The validation cohort was analyzed following a prespecified statistical analysis plan, included in the supplement, using SAS Enterprise Guide 8.2 (SAS 9.4) (SAS Institute, Cary, NC). Performance is presented in terms of positive-predictive-value (PPV), specificity, and F1 scores (36-38). Cochran-Armitage test and

Fisher's exact test were used to assess trends and differences in proportions. Confidence intervals (CIs)

for proportions were calculated using the Clopper-Pearson or bootstrap methods.

Patients included in the development cohort were generally similar to those excluded due to lack of complete data, although rate of intubation and systolic blood pressure were slightly higher and oxygen saturation and D-dimer level lower. Patients included in the validation cohort exhibited higher rates of severe outcomes than patients excluded due to lack of complete data. The included and excluded cohorts are compared in the supplement.

Two-hundred twenty-nine patients were included in the development cohort: 77 (34%) were admitted to the ICU, 53 (23%) were intubated, and 45 (20%) developed ARDS. The proportions of patients experiencing poor outcomes were smaller in the 330 patients in the validation cohort, of whom 85 (26%) were admitted to the ICU, 42 (13%) were intubated, and 35 (11%) developed ARDS. The patient characteristics of the two cohorts are summarized in Table 1 . The racial/ethnic composure of both cohorts were skewed compared with overall Colorado demographics (39) with White being significantly underrepresented in both sets, and Black being overrepresented only in the development cohort. All attributes used in classification are contained in Table 1 and denoted with an asterisk. The time from data collection to ICU admission was estimated in the validation cohort and is summarized in figure 3. Definition of abbreviations: eGFR = estimated glomerular filtration rate; BP = blood pressure; QTc = corrected QT interval; BUN = blood urea nitrogen; CO 2 = carbon dioxide; WBC = white blood cell; LDH = lactate dehydrogenase; CRP = C-reactive protein; BMI = body mass index *Used for classification ** only complete for 205 out 229 patients 

Test development for prediction of ICU admission used the schema in Figure 2B , with the flow of patients through the hierarchical classification scheme shown in Figure 3 . In figure 4 , we see the test classified 73 (32%), 54 (24%), 51 (22%), and 51 (22%) of the development cohort to the lowest, low, high, and highest risk groups, respectively. Only 12% of patients in the lowest risk group were admitted to the ICU, whereas 65% of the highest risk group were admitted. Performance was similar in the validation cohort, of which 28%, 22%, 27%, and 22% were classified to the lowest, low, high, and highest risk groups, respectively. The proportions of patients that were admitted to the ICU were significantly associated with increasing risk subgroup (Cochran-Armitage p < 0.0001). The proportion of patients admitted to the ICU in the lowest risk group was 11% (95% CI: 5%-19%), significantly lower than that in the other groups (Fisher's exact p < 0.0001). The proportion of patients admitted to the ICU in the highest risk group was 51% (95% CI: 39%-63%), Fisher's exact p (highest risk vs other) < 0.0001).

Test classification was associated with heart rate, respiratory rate, oxygen saturation, sodium, blood urea nitrogen (BUN), anion gap, white blood cell (WBC) count, lactate dehydrogenase (LDH), D-dimer, CRP, and ferritin. Shapley Value analysis showed that the attributes most important for classification generation varied by patient, but that lowest risk classification was most often explained by CRP and Ddimer, with ferritin, LDH, platelet count, heart rate, respiratory rate, oxygen saturation, and WBC also of relatively higher importance. In highest risk patients, classification was related to LDH and D-dimer, although oxygen saturation, respiratory rate, CRP, ferritin, and weight were also important for some patients.

Test development for prediction of ARDS used the schema of Figure 2B , with the flow of patients through the hierarchical classification scheme shown in Figure 5 . Note that, for this test, the lowest and lower risk groups were combined into a single lowest risk group, as the proportion of patients with ARDS was found to be similar in both subgroups during test development. In figure 4 , we see the test predicting risk of developing ARDS classified 142 (62%), 47 (21%), and 40 (17%) patients to the lowest, low, and highest risk groups, respectively, in the development cohort. In the lowest risk group, only 8% of patients developed ARDS, while in the highest risk group 45% of patients developed ARDS. The proportions of patients assigned to the lowest, high, and highest risk groups were similar in the Machine Learning COVID-19 Risk Stratification validation cohort: 190 (58%), 73 (22%), and 67 (20%), respectively. The proportion of patients that developed ARDS increased with increasing risk group (Cochran-Armitage p = 0.02). Although the lowest risk group contained more than half of the patients, only 5% (95% CI: 3%-9%) of them developed ARDS (Fisher's exact p (lowest vs other) < 0.0001). In contrast, the percentage of patients developing ARDS in the highest risk group was 27% (95% CI: 17%-39%), Fisher's exact p (highest vs other) = 0.0004.

Each uncolored box represents a classifier with the contents reflecting the set of patients to be classified by the classifier. The colored boxes represent the final risk groups with the contents reflecting composition of the groups and test performance. Bootstrap 95% confidence intervals for performance metrics are given in the supplement. Test classification was associated with age, blood pressure, oxygen saturation, sodium, BUN, WBC, LDH, D-dimer, CRP, and ferritin. Shapley value analysis again showed that the attributes most important for classification generation varied by patient, but that CRP and D-dimer contributed substantially to a classification of lowest risk, with race and age also contributing for some patients. Highest risk classification was related to LDH, CRP, and BUN in most patients and oxygen saturation in some patients.

Test development to predict intubation used the schema of Figure 2A , with the flow of patients through the hierarchical classification scheme shown in Figure 5 . In figure 6 , we see the test predicting risk of intubation classified 74 (32%), 62 (27%), 55 (24%), and 38 (17%) patients of the development cohort to the lowest, low, intermediate, and highest risk groups, respectively and 86 (26%), 120 (36%), 67 (20%), and 57 (17%), respectively, in the validation cohort. The patients of the validation cohort were assigned 86 (26%):120 (36%):67 (20%): 57 (17%) to the lowest, low, high and highest risk groups. Only 1% (95% CI: 0%-6%) of patients in the lowest risk group were intubated (Fisher's exact p (vs other <0.0001), while 33% (95%CI: 21%-47%) of patients in the highest risk group were intubated (Fisher's exact p (vs other) <0.0001 ). There was a significant association of increase in intubation with increasing risk group (Cochran-Armitage p <0.0001).

Test classification was associated with respiratory rate, oxygen saturation, BUN, creatinine, anion gap, WBC, LDH, D-dimer CRP, and ferritin. Shapley value analysis revealed that multiple attributes, varying by patient, were of increased relevance for classification. However, CRP was found to be generally most relevant for generation of a lowest risk classification, with D-dimer, LDH, BUN, race, and age also important factors. A highest risk classification was related to LDH, oxygen saturation, CRP, and BUN.

Each uncolored box represents a classifier with the contents reflecting the set of patients to be classified by the classifier. The colored boxes represent the final risk groups with the contents reflecting composition of the groups and test performance. Bootstrap 95% confidence intervals for performance metrics are given in the supplement. Each uncolored box represents a classifier with the contents reflecting the set of patients to be classified by the classifier. The colored boxes represent the final risk groups with the contents reflecting composition of the groups and test performance. Bootstrap 95% confidence intervals for performance metrics are given in the supplement. 

An attempt was made to compare the performance of the tests to similar published classifiers (8, 10, 15) . The classifier described in Xiao et al. (12) applied on the development cohort yielded very similar areas under the receiver-operating characteristic (ROC) curves to those for the first classifiers in our hierarchies for each endpoint. Using the specified cutoff (10), relatively small, but pure lowest risk groups were observed for all four endpoints. While the purity was similar to that of our tests, the lowest risk group sizes were roughly half the size. The classifier described by Liu et al. (8) used age and NLR to stratify patients into four risk groups. Across all four endpoints, purities in the lowest risk groups were similar to those presented here but were roughly half the size. The highest risk groups were nearly twice the size of those for our tests but had purities a factor of 2-3 smaller. Performance for predicting ICU admission was poor, with the low risk group containing a similar proportion of patients admitted to the ICU as the highest risk group. Many studies have looked at binary classification to similar prognostic endpoints (20-27). While our tests stratify patients into more than 2 groups, the top classifier in each hierarchy achieved comparable performance in terms of AUROC.

Using EHR-derived data recorded at the time of hospital admission, we developed and blindly validated a clinical decision support system composed of three different ML-based risk tests predicting three measures of progression to severe disease in patients hospitalized with COVID-19; namely risk of progression to ICU admission, intubation, and ARDS diagnosis. Given that many patients admitted with COVID-19 may not be in regular care and aware of comorbidities or may be critically ill upon presentation and unable to provide a detailed medical history, we utilized only attributes readily accessible in an emergency care setting.

Multiple previous studies have used ML-based algorithms to predict COVID-19 prognosis by combining basic patient demographics, vital signs, laboratory measurements, and comorbidities (14) (15) (16) , sociodemographic information, comorbidities and current medications (19) , or chest computed tomography (CT) scan alone (18, 19) or with patient demographics (15) . The performance of our tests compared favorably with that of two existing risk assessment models for which we were able to generate classifications for our development set, with our test achieving similar negative predictive values in the lowest risk groups but superior specificity. However, for other simple nomogram-based models, we were not able to compare performance due to lack of information for required attributes, as these were not obtainable from collected EHR data.

We validated three tests by generating test classifications blinded to all outcome data and analyzing the results according to a prespecified statistical analysis plan. This validation study was possible using data directly extracted from the EHR, without any further curation, demonstrating that the data required for risk assessment was easily and readily accessible. Test performance was similar between the development and validation cohorts, illustrating the ability of the ML platform to generalize to unseen datasets. The successful validation of the performance of our models observed in test development shows that our selection of minimal attributes was rich in predictive information. These observations were consistent with the associations we observed when we compared patient characteristics between our risk subgroups (see supplement). However, the Shapley values also revealed that our tests combined information across the 26 attributes in non-trivial ways and the attributes that explained patient classification differed from patient to patient. For some patients, all attributes had similar importance, while for others, some attributes pointed towards higher risk, while others pointed towards lower risk.

In contrast to the single center development cohort, the validation cohort included patients from the statewide UC health system. However, the cohort size and restriction to Colorado are limitations of this study. While patients excluded from the development cohort due to missing data were generally similar to those included, in validation, patients with complete data (only 15% of the total available) exhibited higher rates of severe disease and generally worse prognostic factors (laboratory and vital signs) than those without. Further validation of the tests in larger cohorts derived from other health systems and geographic areas is necessary.

The clinical utility of these tests will depend on their application. All tests achieved good performance in identifying patients who did not experience adverse outcome in the lowest risk groups in development and validation. Performance in identifying patients who experienced adverse outcomes in the highest risk groups was promising, but the risks of false positives and negatives would need to be carefully considered in an application where identifying patients likely to experience adverse outcome is desired.

In summary, we have developed and validated a suite of tests able to assess the risk of a poor outcome for patients hospitalized with COVID-19 based on information easily and routinely collected at time of hospital admission. Additional validation, preferably in a prospective setting, is required to further demonstrate the clinical utility of this risk assessment tool beyond clinical assessment alone. However, with readily-derived and quickly-available EHR data, a risk assessment at or near the time of admission can inform prognosis, guide discussions on the risks and benefits of treatments (including intubation), or identify low or high-risk patients for limited resources or enrollment in clinical trials. Furthermore, the methods here may be implemented in the care of future patients with novel viral infections. 

The training data cohort contained patients aged 18 or older admitted to the University of Colorado

Hospital patients with positive COVID-19 nasopharyngeal polymerase chain reaction (PCR) between mid-March 2020 and mid-May 2020. Patient information was extracted from electronic medical records by medical students and stored in a REDCap project (E1 Table E1 . Figure E1 . For this study, the emergency department and basic bloodwork numeric features are used to train the nominal Diagnostic Cortex master classifiers, and the basic patient characteristics are combined with the master classifier output in the decision trees.

Referring to Figure E1 , in each sampling of the reserved set, a classification tree was grown on Training Set 2 and the test set was evaluated with it. The data was split into 1/3 for Training Set 1, 2/3 for reserve, and then equal proportions of the subsequent splits of the reserve to Training Set 2 and the test set. In all samplings, an equal number of patients with the endpoint of interest were kept in each group.

The attributes passed to each tree were: the output of the Diagnostic Cortex Master Classifier (binarized with a cutoff at 0.5 and treated as categorical), age, gender, and race. Interaction terms were calculated between the binarized Diagnostic Cortex output and each of gender and race and passed to the trees as additional attributes. These interaction terms consist of categories representing each observed combination of the categories in the variables used to calculate them (eg gender = 'male' and Master

Classifier output = 0)

The procedure for growing the classification trees for this study was as follows:

1. For non-categorical features, the values of each feature were sampled to get a list of feature values to consider when splitting each node in the tree. The values were taken to be the 10 th , 20 th , …, 90 th percentile of observed feature values in the training set.

2. The training set was recursively split: The entire training set was assigned to the initial node.

The procedure for each recursive node split was as follows:

a. Sample the features in the training set: Take Hyperparameter optimization was not performed. We have found in past work (E2) that the algorithm is not very sensitive to the choice of hyperparameters. Instead, the parameters were picked on general heuristic considerations. We believe this to be safer than overoptimizing hyperparameters in this setting which has a relatively small number of training examples.

 The number of training/test splits of the data defining bags and the proportion of samples used for training is chosen based on a trade-off between maintaining enough samples to adequately represent the population and providing diversity amongst the ensemble samplings. We have found that using 2/3 for training accomplishes this sufficiently well. When using the additional decision trees, we split that 2/3 so that 1/3 trains the master classifier and 1/3 trains the ensemble of trees in each bag. Given this proportion, the number of bags is chosen so that each sample is out of bag sufficiently many times to allow for reliable out-of-bag estimates on the development set. With the training ratio of 2/3, 325 training/test splits allows for each sample to be in a test set an expected number of roughly 100 times. We have found that a choice of 625 bags provides even more confidence that the out-of-bag estimates are reliable when computational resources allow.

 The kNN classifiers use a Euclidean distance and k=11. The optimal choice for k is commonly taken to be the square root of the number of training samples (E3, E4).

 The number of atomic classifiers selected in each dropout iteration should be smaller than the number of samples in the training set, and the smaller it is, the greater the regularization strength. We have found a choice of 10 to be optimal in settings where there are on the order of thousands or more atomic classifiers to sample. The choice of 10 in this setting is more conservative (stronger regularization) than we have used in the past. Given the choice of the number of atomic classifiers in each dropout iteration, the number of dropout iterations should be selected such that each atomic classifier is sampled multiple times, typically between 10-100.

The choice of 100,000 dropout iterations is sufficient to meet that goal here. Figure E3 : Hierarchical Configuration with an Intermediate Split: A Diagnostic Cortex with in-bag decision tree model is used to split the entire development set into a higher and lower risk group for the endpoint. Diagnostic Cortex models without trees are used to split the two groups from the first split into four. The lowest risk group is defined as a low risk classification by the first classifier and then a low risk classification by the second low risk classifier, and similar for the highest risk group. The other two groups are recombined and then another Diagnostic Cortex model is used to split this group into the final high and low risk groups.

The Explainability research has moved away from trying to provide a global description of relative attribute importance accurate for all possible sets of input data, which is unlikely to be successful, given the complexity and nonlinearities inherent in most ML approaches, to a local approach of assessing relative attribute importance for the result for a specific set of input data. In the case of molecular tests, this latter approach corresponds to providing a description of the relative importance of the attributes used to the result generated for an individual patient. An alternative approach to explainability makes use of game theory concepts developed for determining the equitable distribution of winnings between players working in teams. Parallels between deciding on a fair distribution of winnings between team members in multiplayer games and assessing the relative importance of multiple input attributes to the result of a ML algorithm were observed several years ago. Unfortunately, the exact evaluation of SVs for ML algorithms using more than a handful of attributes is generally unfeasible. There are two main issues that arise:

1. The requirement to sum over all possible subsets of attributes This is a task of exponential complexity. For a set of attributes of size there are | |, 2 | | -1 subsets that we have to sum over to find the SV for each member of { }. for classifier retraining (point 2 above) and so allows the calculation of approximations to SVs using Monte Carlo-based sampling to address point 1. Hence, we were able to generate SVs for the Diagnostic Cortex portions of the risk assessment classifiers using the sampling method of (E13) With 500,000

Monte Carlo sampling steps.

The remaining parts of the risk assessment classifiers were ensemble averages of trees constructed using only a very small number of attributes. The small number of attributes allowed an exact SV Machine Learning COVID-19 Risk Stratification calculation over the exponential number of terms in the sum, with model retraining for each attribute subset.

SVs were evaluated for each of the classifiers used in each of the risk assessment tests for 50 patients from the validation cohort. Patients were selected so that there was somewhat equal representation across all possible test risk groups and endpoints. Race and gender were also considered in the selection, but representative populations across these attributes was secondary to risk group and endpoint. The ARDS classifier has only three final risk groups: lowest risk, high risk, and highest risk. Endpoint data for this validation analysis is only expected for ICU admission, intubation, and development of ARDS, but labels for risk of developing any complication will still be provided incase that endpoint data proves to be extractable at a later date.

The study population includes all patients hospitalized with COVID-19 for whom test classifications could be generated from data extracted from UC Health Data Compass and received on 10/09/2020 and for whom at least one of the endpoints (i) admission to ICU (yes/no) and (ii) intubation (yes/no) is provided after unblinding.

Machine Learning COVID-19 Risk Stratification

The statistical analyses contained in this SAP will be carried out using SAS (SAS9.4 or higher), GraphPad PRISM (PRISM 8 or higher), or Matlab2020. All analyses will be verified by an independent analyst. The results of all analyses will be contained in a final report containing this SAP as an appendix.

Additional ad hoc analyses may be performed and may be included in the final report, but will be cleared marked as outside the scope of this SAP.

Primary Analysis 

Note that all results for the development cohort were obtained using out-of-bag estimates [E13]. Prediction of acute respiratory distress syndrome (ARDS) the cutoff value of 0.5 marked for each. AUCs are also given in the legends. Tables E15 and E16 respectively summarize the categorical and continuous attributes used in prediction for each of the final risk groups of the ARDS test in development. Tables E17 and E18 give the same in the validation set.

Mann-Whitney p-values are given comparing the continuous attribute ranks between the highest and lowest risk groups compared to all other risk groups. These statistics were calculated using Matlab

R2020a. In the validation cohort, for race, a chi-squared test of independence was calculated with race grouped as: white, black, Hispanic, and other. The p-value was 0.519. For EGFR and gender, a Fisher exact test was used yielding p-values of 0.0189 and 0.0405 respectively. These statistics were calculated in SAS Enterprise Guide 8.2 (SAS 9.4). Figure E17 schematically shows how the patients are split into the four final groups.

Sixty-eight patients out of the 229 in the development set developed a complication. The initial binary classifier separated these patients into a lower and higher risk group. The lower risk group had 127 patients of which 26 developed a complication. The higher risk group had 135 patients of which 22developed a complication. Both groups were split again into higher and lower risk groups using the high and low risk child classifiers.

Patients from the lower risk group that were classified as lower risk by the low risk child classifier were assigned to the lowest risk final group consisting of 73 patients of which 9 developed a complication.

The remaining lower risk group patients were assigned to the final low risk group consisting of 60 patients of which 13 developed a complication.

Patients from the higher risk group who were classified as higher risk by the high risk child classifier were assigned to the highest risk final group, consisting of 40 patients of whom 23 developed a complication. The remaining higher risk group patients were assigned to the final high risk group, consisting of 54 patients of whom 23 developed a complication.

Tables E25 and E26 summarize selected attributes by final group classification.

Machine Learning COVID-19 Risk Stratification In reading figure E18 showing the Shapley values for the test predicting risk of developing ARDS, some broad conclusions can be drawn. For example, we see that the Diagnostic Cortex attribute in the trees plays a significant role in assigning both higher and lower risk classifications in the initial binary classifier.

Gender does not seem to play a role at all, and race, age, and weight play a significant role for some patients. Looking at corresponding Diagnostic Cortex SVs, we see that LDH, CRP, and BUN all frequently contribute to a higher risk classification while CRP and D-dimer frequently contribute to a lower risk classification, in addition to several other attributes to a lesser extent. For patients that are classified as low risk by the initial binary classifier, the low risk child classifier diagram shows CRP and D-dimer contributing significantly again to a lower risk classification. From this, we could conclude that for many patients that get a lowest risk final classification, CRP and D-dimer contributed substantially, with race and age also contributing a fair amount for some patients. Focusing on the highest risk group, the high risk child classifier shows LDH and oxygen saturation contributing to high risk classification of many patients. So, for a final test label of highest risk, LDH, CRP, BUN, and oxygen saturation substantially contribute.

SVs can also be plotted simultaneously with attribute values. Figure E21 shows a scatter plot of SV and CRP value colored by corresponding classification (blue is lower risk and red is higher risk). We see that generally lower values of CRP correspond to lower risk of developing ARDS.

While race/ethnicity was not observed to be among the strongest contributors to risk classification, it was still of interest to investigate further. Figure E22 shows the SVs for race/ethnicity in the first split classifier of the ARDS test separated by race/ethnicity choice. We see that a choice of white corresponds to a contribution towards a lower risk classification while all other choices do not generally contribute towards risk classification. SVs for the test predicting risk of admission to the ICU are shown in figure E19 . Again, the Diagnostic Cortex component contributes heavily for assigning both lower and higher risk with weight contributing to a higher risk classification for some patients and race contributing to a lower risk classification for some patients. Gender plays more of a role but is still not as pronounced as the other attributes. The

Diagnostic Cortex component of the initial binary classifier shows LDH and CRP playing the largest role in assigning a higher risk classification, but several other features contribute as well. Many attributes contribute to a lower risk classification with ferritin, CRP, D-dimer, LDH, and platelet count seemingly playing more of a role than heart rate, respiratory rate, oxygen saturation and WBC. The low risk child classifier shows CRP and D-dimer contributing to a lower risk classification, so for a final risk label of lowest risk, CRP and D-dimer are perhaps the most important, and ferritin, LDH, platelet count, heart rate, respiratory rate, oxygen saturation, and WBC also contribute. The high risk child classifier shows oxygen saturation, respiratory rate, LDH, CRP, and ferritin contributing to a higher risk classification, so LDH and D-dimer are perhaps the most important with oxygen saturation, respiratory rate, CRP, ferritin, and weight also contributing.

SVs for the test predicting the risk of intubation are shown in figure E20 . Again, the Diagnostic Cortex component contributes heavily for assigning both lower and higher risk, with race and age also contributing to a lower risk classification for some patients. The Diagnostic Cortex SVs show LDH, CRP and BUN contributing to a higher risk classification and CRP, D-dimer, LDH, and BUN contributing to a lower risk classification. The low risk child classifier shows CRP contributing to a lower risk classification; so, for a final classification of lowest risk, CRP is likely the most important, with D-dimer, LDH, BUN, race, and age also contributing. The high risk child classifier shows oxygen saturation and LDH contributing to a higher risk classification, so LDH seems to be the most important contributor for a classification of highest risk with oxygen saturation, CRP, and BUN also contributing.

Overall, we see that each of the tests is producing a classification based on a complex interplay of multiple attributes and that, while we can discern some general trends across the cohort, the relative importance of the attributes to classification is dependent on the patient.

The preceding arguments tried to consider how the attributes affected the classification of samples in aggregate. These arguments were fairly general; we believe the information at the patient level is more directly interpretable and can be very informative for personalized treatment options. Figures Comments:

Patient at lower risk of intubation in first split from CRP, D-dimer, LDH, and oxygen saturation, but higher risk from weight. Child low risk split shows higher risk from BUN anion gap, respiratory rate, BPs, heart rate, and temperature, but lower risk from

Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients

Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network metaanalysis

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

Clinical course and risk factors for mortality of adult inpatients with COVID-10 in Wuhan, China: a retrospective cohort study

Early predictors of clinical outcomes of COVID-19 outbreak in

Risk Factors for Hospitalziation, Mechanical Ventilation, or Death Among 10 131 US Veterans with SARS-CoV-2 Infection

Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort

Neutrophil-tolymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics

Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019

Machine Learning Classifier Models Can Identify Acute Respiratory Distress Syndrome Phenotypes Using Readily Available Clinical Data

Machine Learning Classifier Models: The Future for Acute Respiratory Distress Syndrome Phenotyping? Am J Respir Crit Care Med

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

Laboratory Findings Associated With Severe Illness and Mortality Among Hospitalized Individuals With Coronavirus Disease 2019 in Eastern Massachusetts

Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicenter study

Model Development and Validation

Machine learning prediction for mortality of patients diagnosed with COVID-19: a nationwide Korean cohort study. Sci Rep

A Quantitative Lung Computed Tomography Image Feature for Multi-Center Severity Assessment of COVID-19

A fully automatic deep learning system for COVID_19 diagnostic and prognostic analysis

Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients

Early risk assessment for COVID-19 patients from emergency department data using machine learning

Machine learning methods to predict mechanical ventilation and mortality in patients with COVID-19